Creating innovative and sustainable health solutions
O3 Holding GmbH is the listed holding company of KD Pharma Group, a leading CDMO in pharmaceutical and nutritional lipids, headquartered in Switzerland with manufacturing facilities in the UK, Norway, Germany, Canada, Peru, and the US.
We at KD Pharma Group are proud to be the largest and most competitive CDMO for pharmaceutical and nutritional marine lipids in the world. This allows us to advance our mission of creating innovative and sustainable health solutions that help people live better lives.
We aim to provide investors with the latest reports and relevant information about the KD Pharma Group, through quarterly reports and presentations.
O3 Holding GmbH: Public Bond Issuance
On 2 October 2024, O3 Holding GmbH successfully placed a EUR 180 million senior secured bond due 10 October 2029. The bond will pay a quarterly floating rate coupon of 3-month EURIBOR + 5.25% per annum.
The bond is included under ISIN NO0013360552 in the Open Market (Freiverkehr) of the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) and is expected to subsequently be listed on the Oslo Stock Exchange (Oslo Børs).
Prospectus coming soon
Reports
O3 Holding GmbH (KD Pharma Group) publishes a financial update once a quarter, with current key figures on the Group. Here you will find the published financial reports.
.
Governance
We are fully committed to good corporate governance.
Good governance is deeply rooted in our corporate culture. The Management Board of the KD Pharma Group uphold the principles of modern corporate governance.
See documents:
Contact
We are pleased to assist with any inquiries you may have regarding Investor Relations. Contact us at: